Research News
The U.S. Food and Drug Administration has approved a new treatment for glaucoma, iDose® TR (travoprost intracameral implant, 75 mcg). iDose TR is a first-of-its kind treatment that is designed to provide up to three years of 24/7, continuous drug therapy directly inside the eye, helping people with glaucoma take control over the elevated eye pressure associated with this vision disease.
In a new BrightFocus-funded study, researchers found an association between alterations in circadian rest-activity rhythms and risk of frailty incidence in older adults.
BrightFocus Foundation’s Alzheimer’s Fast Track, an immersive workshop for early-career scientists, was held Nov. 8-10 in Washington, D.C. and convened 80 talented Alzheimer’s researchers from 19 U.S. states and six countries, including Japan, Spain, and Sweden.
To achieve true health equity, we must ensure that all populations have equitable access to clinical trials and the benefits of medical research. With the right mix of resources, dedication, compassion, patience, and time, we can positively impact communities nationwide, write BrightFocus President and CEO Stacy Pagos Haller and board member Tonya M. Matthews, PhD, in a new op-ed.
In a first of its kind study, BrightFocus-funded researchers have identified a possible new way to improve drugs to treat glaucoma by studying a tiny part of the eye’s drainage system that plays a major role in eye pressure.
A potential drug rooted in initial grant funding from BrightFocus Foundation to Dr. Ilyas Washington gives hope to those suffering from Stargardt disease, a genetic form of macular degeneration.
Researchers have found a way to block a “master switch” in the eye and the brain that controls inflammation, introducing a possible target for combatting glaucoma and other neurodegenerative diseases.
An updated drug shows promise in treating traumatic brain injuries that can lead to neurodegenerative diseases.
Researchers have successfully demonstrated that hagfish slime proteins can accurately replicate membranes in the human eye.
A team of researchers including Alzheimer’s Disease Research grantee Eunhee Kim, PhD, have used a 3D brain cell culture model to show that the exercise-induced muscle hormone, irisin, reduces the level of amyloid beta associated with Alzheimer’s disease.
